Cardiovascular involvement has been described in acute and recovered COVID-19 patients. Here, we present a case of symptomatic pericarditis with persistent symptoms for at least six months after the acute infection and report 66 published cases of pericarditis in discharged COVID patients. Patient mean age ± SD was 49.7 ± 13.3 years, ranging from 15 to 75 years and 57.6% were female. A proportion of 89.4% patients reported at least one comorbidity, with autoimmune and allergic disorders, hypertension and dyslipidaemia, as the most frequent. Only 8.3% of patients experienced severe symptoms of acute COVID-19. The time between acute COVID and pericarditis symptoms varied from 14 to 255 days. Chest pain (90.9%), tachycardia (60.0%) and dyspnoea (38.2%) were the most frequent symptoms in post-acute pericarditis. A proportion of 45.5% and 87% of patients had an abnormal electrocardiogram and abnormal transthoracic ultrasound, respectively. Colchicine combined with non-steroidal anti-inflammatory drug (NSAID) or acetylsalicylic acid (aspirin) were prescribed to 39/54 (72%) patients. Of them, 12 were switched to corticosteroid therapy due to non-response to the first-line treatment. Only 6 patients had persisting symptoms and were considered as non-respondent to therapy.Our report highlights that pericarditis should be suspected in COVID-19 patients with persistent chest pain and dyspnoea when pulmonary function is normal. Treatment with non-steroidal anti-inflammatory and colchicine is usually effective but corticosteroids are sometimes required.

中文翻译：

---

与急性新冠病毒感染后相关的心包炎：病例报告及文献综述。

在急性和康复的 COVID-19 患者中已有心血管受累的报道。在此，我们介绍一例急性感染后症状持续至少六个月的症状性心包炎病例，并报告了 66 例已发表的出院新冠患者心包炎病例。患者平均年龄±SD为49.7±13.3岁，范围从15岁到75岁，其中57.6%为女性。89.4% 的患者报告至少一种合并症，其中最常见的是自身免疫和过敏性疾病、高血压和血脂异常。只有 8.3% 的患者出现了急性 COVID-19 的严重症状。急性新冠肺炎和心包炎症状之间的时间间隔为 14 至 255 天。胸痛（90.9%）、心动过速（60.0%）和呼吸困难（38.2%）是急性心包炎后最常见的症状。比例为45。分别有5%和87%的患者心电图异常和经胸超声异常。39/54 (72%) 的患者接受了秋水仙碱联合非甾体类抗炎药 (NSAID) 或乙酰水杨酸（阿司匹林）的治疗。其中 12 人因一线治疗无反应而转用皮质类固醇治疗。只有 6 名患者有持续症状，被认为对治疗无反应。我们的报告强调，当肺功能正常时，出现持续性胸痛和呼吸困难的 COVID-19 患者应怀疑心包炎。非类固醇抗炎药和秋水仙碱治疗通常有效，但有时需要皮质类固醇。39/54 (72%) 的患者接受了秋水仙碱联合非甾体类抗炎药 (NSAID) 或乙酰水杨酸（阿司匹林）的治疗。其中 12 人因一线治疗无反应而转用皮质类固醇治疗。只有 6 名患者有持续症状，被认为对治疗无反应。我们的报告强调，当肺功能正常时，出现持续性胸痛和呼吸困难的 COVID-19 患者应怀疑心包炎。非类固醇抗炎药和秋水仙碱治疗通常有效，但有时需要皮质类固醇。39/54 (72%) 的患者接受了秋水仙碱联合非甾体类抗炎药 (NSAID) 或乙酰水杨酸（阿司匹林）的治疗。其中 12 人因一线治疗无反应而转用皮质类固醇治疗。只有 6 名患者有持续症状，被认为对治疗无反应。我们的报告强调，当肺功能正常时，出现持续性胸痛和呼吸困难的 COVID-19 患者应怀疑心包炎。非类固醇抗炎药和秋水仙碱治疗通常有效，但有时需要皮质类固醇。只有 6 名患者有持续症状，被认为对治疗无反应。我们的报告强调，当肺功能正常时，出现持续性胸痛和呼吸困难的 COVID-19 患者应怀疑心包炎。非类固醇抗炎药和秋水仙碱治疗通常有效，但有时需要皮质类固醇。只有 6 名患者有持续症状，被认为对治疗无反应。我们的报告强调，当肺功能正常时，出现持续性胸痛和呼吸困难的 COVID-19 患者应怀疑心包炎。非类固醇抗炎药和秋水仙碱治疗通常有效，但有时需要皮质类固醇。